New hope for rare cancer: drug duo tested after chemo fails
NCT ID NCT04710628
Summary
This study tested whether combining two existing cancer drugs, pembrolizumab and lenvatinib, could help control advanced thymic cancer that had worsened after standard chemotherapy. It enrolled 43 adults whose cancer could not be cured by surgery or radiation. The main goal was to see if the combination could stop the cancer from growing for at least 5 months while monitoring side effects.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for METASTATIC THYMIC CARCINOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
A.O.U. San Luigi Gonzaga
Orbassano, Italy
-
Centre Hospitalier Universitaire de Toulouse
Toulouse, France
-
Centre Oscar Lambert
Lille, France
-
Complejo Hospitalario Universitario A Coruña (CHUAC)
A Coruña, Spain
-
Hospital Clinic i Provincial de Barcelona
Barcelona, 08036, Spain
-
Hospital Sant Creu i Sant Pau
Barcelona, Spain
-
Hospital Universitari i Politècnic La Fe
Valencia, Spain
-
Hospital Universitario La Paz
Madrid, Spain
-
Hospital Universitario Virgen del Rocío
Seville, Spain
-
Hôpitaux Universitaires de Marseille - Hôpital Nord
Marseille, France
-
IGR Gustave Roussy
Villejuif, France
-
Institut Bergonié
Bordeaux, France
-
Institut Curie
Paris, France
Conditions
Explore the condition pages connected to this study.